Artal Group S.A. Bio N Tech Se Call Options Transaction History
Artal Group S.A.
- $1.58 Billion
- Q2 2024
Call Options
1 transactions
Others Institutions Holding BNTX
# of Institutions
328Shares Held
40.6MCall Options Held
845KPut Options Held
1.23M-
Baillie Gifford & CO8.28MShares$983 Million0.53% of portfolio
-
Primecap Management CO Pasadena, CA4.79MShares$569 Million0.28% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.38MShares$520 Million1.49% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.93MShares$348 Million1.34% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$225 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $28.8B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...